TELIX PHARM (TLPPF) Stock Price, News & Analysis

Telix Pharmaceuticals Limited (traded in the U.S. under the symbol TLPPF) is a foreign private issuer that files reports with the U.S. Securities and Exchange Commission (SEC) under the Securities Exchange Act of 1934. The company submits current reports on Form 6-K and indicates that it files its annual reports on Form 20-F. Telix Pharmaceuticals Limited is associated with announcements made to the Australian Securities Exchange (ASX), reflecting its reporting obligations in Australia as well as in the United States.

According to its SEC filings, Telix Pharmaceuticals Limited is based in North Melbourne, Victoria, Australia. In multiple Form 6-K filings, the company notes that it has released announcements in Melbourne, Australia, which are then furnished to the SEC as exhibits. These filings connect Telix to activities and disclosures made in its home market while also making that information available to U.S. investors.

Regulatory reporting and disclosures

Telix Pharmaceuticals Limited regularly furnishes Form 6-K reports to the SEC. These filings typically state that an announcement was filed with the Australian Securities Exchange and then attached to the Form 6-K as an exhibit. Examples of such announcements include a presentation for the JP Morgan Healthcare Conference, portfolio updates, study status reports, and revenue-related guidance updates. Each of these announcements is identified in the Form 6-K by a title and attached as an exhibit, often labeled as Exhibit 99.1.

The company’s filings show that Telix Pharmaceuticals Limited uses Form 6-K to provide U.S. investors with access to information that has been publicly released in Australia. The filings specify that Telix has chosen to file annual reports under cover of Form 20-F, which is the standard annual reporting form for many foreign private issuers in the United States.

Examples of disclosed topics in Form 6-K filings

Telix Pharmaceuticals Limited has furnished Form 6-K reports that reference a range of topics described in the attached ASX announcements. These include:

• A “Telix JP Morgan Healthcare Conference 2026 Presentation,” indicating that the company prepared a presentation for that healthcare-focused conference and filed the associated announcement with the ASX before furnishing it to the SEC.
• A “Precision Medicine Portfolio Update: Illuccix China Phase 3 Study, TLX101-CDx and TLX250-CDx FDA Resubmissions,” described as a press release attached as Exhibit 99.1. This shows that Telix has communicated information about a precision medicine portfolio and specific items identified in the title of the announcement.
• Announcements titled “ProstACT Global Study Status” and “1st Patient Dosed in ProstACT Global Randomized Tx Expansion,” each described as press releases attached as Exhibit 99.1, indicating that Telix has reported on the status and progress of a study referred to as ProstACT Global.
• An announcement titled “Telix Reports US$206M Revenue, FY 2025 Guidance Upgraded,” attached as a press release in a Form 6-K, showing that Telix has communicated revenue information and guidance updates through its ASX announcements and then furnished that information to the SEC.
• An announcement titled “CMS Grants Transitional Pass-Through Status for Gozellix,” attached as a press release, indicating that Telix has reported on a regulatory or reimbursement-related development described in the title.

While the detailed contents of these announcements are contained in the attached exhibits, the Form 6-K cover pages confirm the titles and nature of the information that Telix Pharmaceuticals Limited has chosen to furnish to U.S. investors.

Use of Form 6-K and Form 20-F

In each of the provided Form 6-K filings, Telix Pharmaceuticals Limited indicates that it files annual reports under cover of Form 20-F by checking the corresponding box on the cover page. Form 6-K is used to furnish information that the company has made public in its home jurisdiction, filed with a stock exchange, or distributed to security holders. The repeated use of Form 6-K suggests that Telix uses this mechanism to keep U.S. market participants informed of announcements first made to the Australian Securities Exchange.

The filings also show that Telix Pharmaceuticals Limited identifies itself as a foreign issuer and that its English name is Telix Pharmaceuticals Limited, as stated on the cover pages of the Form 6-K reports. This provides clarity for investors who may encounter the company under different naming conventions in various markets.

Geographic and market context

Based on the Form 6-K cover pages, Telix Pharmaceuticals Limited is located in North Melbourne, Victoria, Australia. The filings repeatedly reference Melbourne, Australia as the place where announcements are made before being filed with the Australian Securities Exchange. The company’s association with the JP Morgan Healthcare Conference and the titles of its announcements indicate that it participates in events and communications that are relevant to healthcare and capital markets audiences.

The U.S. trading symbol TLPPF provides a way for investors to access Telix Pharmaceuticals Limited in U.S. markets, while the SEC filings connect that symbol to the company’s regulatory and disclosure activities. The combination of ASX announcements and SEC Form 6-K reports offers a structured path for investors to review Telix’s public communications.

How investors can use this information

Investors researching TLPPF can review the company’s Form 6-K filings to see the titles and attached exhibits of announcements first made to the Australian Securities Exchange. These documents provide insight into topics such as conference presentations, portfolio updates, study status communications, revenue announcements, and other matters that Telix Pharmaceuticals Limited has chosen to disclose. The indication that Telix files annual reports on Form 20-F also signals where more extensive annual information may be found.